Show simple item record

dc.contributor.authorNorsker, Filippa Nyboe
dc.contributor.authorRechnitzer, Catherine
dc.contributor.authorCederkvist, Luise
dc.contributor.authorHolmqvist, Anna Sällfors
dc.contributor.authorTryggvadottir, Laufey
dc.contributor.authorMadanat-Harjuoja, Laura-Maria
dc.contributor.authorØra, Ingrid
dc.contributor.authorThorarinsdottir, Halldora K
dc.contributor.authorVettenranta, Kim
dc.contributor.authorBautz, Andrea
dc.contributor.authorSchrøder, Henrik
dc.contributor.authorHasle, Henrik
dc.contributor.authorWinther, Jeanette Falck
dc.date.accessioned2019-01-03T10:50:42Z
dc.date.available2019-01-03T10:50:42Z
dc.date.issued2018-12-15
dc.date.submitted2019-01
dc.identifier.citationSomatic late effects in 5-year survivors of neuroblastoma: a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia study. 2018, 143(12):3083-3096 Int J Canceren_US
dc.identifier.issn1097-0215
dc.identifier.pmid29926896
dc.identifier.doi10.1002/ijc.31631
dc.identifier.urihttp://hdl.handle.net/2336/620779
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractBecause of the rarity of neuroblastoma and poor survival until the 1990s, information on late effects in neuroblastoma survivors is sparse. We comprehensively reviewed the long-term risk for somatic disease in neuroblastoma survivors. We identified 721 5-year survivors of neuroblastoma in Nordic population-based cancer registries and identified late effects in national hospital registries covering the period 1977-2012. Detailed treatment information was available for 46% of the survivors. The disease-specific rates of hospitalization of survivors and of 152,231 randomly selected population comparisons were used to calculate standardized hospitalization rate ratios (SHRRs) and absolute excess risks (AERs). During 5,500 person-years of follow-up, 501 5-year survivors had a first hospital contact yielding a SHRR of 2.3 (95% CI 2.1-2.6) and a corresponding AER of 52 (95% CI 44-60) per 1,000 person-years. The highest relative risks were for diseases of blood and blood-forming organs (SHRR 3.8; 95% CI 2.7-5.4), endocrine diseases (3.6 [3.1-4.2]), circulatory system diseases (3.1 [2.5-3.8]), and diseases of the nervous system (3.0 [2.6-3.3]). Approximately 60% of the excess new hospitalizations of survivors were for diseases of the nervous system, urinary system, endocrine system, and bone and soft tissue. The relative risks and AERs were highest for the survivors most intensively treated. Survivors of neuroblastoma have a highly increased long-term risk for somatic late effects in all the main disease groups as compared to background levels. Our results are useful for counseling survivors and should contribute to improving health care planning in post-therapy clinics.en_US
dc.description.sponsorshipDanish Cancer Society's Scientific Committee Danish Childhood Cancer Foundationen_US
dc.language.isoenen_US
dc.publisherWiley-Lissen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/full/10.1002/ijc.31631en_US
dc.subjectNeuroblastomaen_US
dc.subjectcancer epidemiologyen_US
dc.subjectchildhood cancer survivorsen_US
dc.subjectpopulation-based cohort studyen_US
dc.subjectsomatic late effectsen_US
dc.subjectKrabbameinen_US
dc.subjectBörnen_US
dc.subjectFylgikvillaren_US
dc.subject.meshNeuroblastomaen_US
dc.titleSomatic late effects in 5-year survivors of neuroblastoma: a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia study.en_US
dc.typeArticleen_US
dc.contributor.department1 Danish Cancer Society, Danish Cancer Society Research Center, Copenhagen, Denmark. 2 Department of Pediatrics, Copenhagen University Hospital, Copenhagen, Denmark. 3 Pediatric Oncology and Hematology, Skåne University Hospital, Lund, Sweden. 4 Department of Clinical Sciences, Lund University, Lund, Sweden. 5 Icelandic Cancer Registry, Reykjavik, Iceland. 6 Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland. 7 Pediatric Oncology, National University Hospital of Iceland, Reykjavik, Iceland. 8 University of Helsinki and Hospital for Children and Adolescents, Helsinki, Finland. 9 Aarhus University Hospital, Department of Pediatrics, Skejby, Aarhus, Denmark.en_US
dc.identifier.journalInternational journal of canceren_US
dc.rights.accessLandspitali Access - LSH-aðganguren_US
dc.departmentcodePED12
dc.source.journaltitleInternational journal of cancer


This item appears in the following Collection(s)

Show simple item record